
Opinion|Videos|October 16, 2024
Patient Education and Emerging Therapies
Key Takeaways
- Clear communication and personalized care plans enhance patient understanding and adherence to treatment for type 2 inflammatory conditions.
- Utilizing tailored educational resources ensures patients comprehend their condition and the importance of adhering to treatment plans.
Panelists discuss how health care providers can improve patient education and support for type 2 inflammatory conditions through personalized communication strategies and shared decision-making, while also evaluating the role of emerging biologic therapies in treatment plans based on individual patient factors, disease severity, and biomarker profiles.
Advertisement
Episodes in this series

- How can health care providers better educate and support patients in understanding type 2 inflammatory conditions and adhering to treatment plans?
- What are your perspectives on the emerging biologic therapies targeting type 2 inflammation? How do you determine when these treatments may be appropriate for your patients?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.

Non-US-born adults had higher CRC screening nonadherence than US-born adults, particularly those with less than 15 years of US residence.
Advertisement
Advertisement
Trending on AJMC
1
Emerging Threats to Cell and Gene Therapy Access
2
FDA Grants Accelerated Approval to Neladalkib for Previously Treated ALK-Positive NSCLC
3
Atopic Dermatitis Escalation Stalls on Payer Rules, Thin Tracking
4
Tirzepatide Lowers BMI by 18.5% in Adolescents With Obesity
5



